Document Detail

The safety of bromocriptine in hyperprolactinaemic female infertility: a literature review.
MedLine Citation:
PMID:  3525009     Owner:  NLM     Status:  MEDLINE    
The dopamine agonist bromocriptine has been widely used to facilitate pregnancy in hyperprolactinaemic women, with a success rate of 80% in relevant cases. Neither the inappropriate hyperprolactinaemia consequent upon bromocriptine withdrawal after conception nor the relative hypoprolactinaemia caused by treatment throughout gestation appears to affect adversely the course and outcome of pregnancy or the endocrine status of the fetus. No teratogenic effect of bromocriptine has been evidenced in humans, and no disturbances in the physical, psychomotor, and intellectual development of the offspring have been observed. Pituitary-tumor enlargement during closely supervised pregnancies very rarely leads to severe and irreversible complications; both the re-institution of bromocriptine treatment in the event of tumor enlargement and its preventive use throughout pregnancy have been shown to be effective measures. It is interesting, moreover, that a reduction of hyperprolactinaemia, compared with pregestational levels, may be seen after bromocriptine-facilitated pregnancies.
C Weil
Related Documents :
3953709 - Cushing's syndrome in pregnancy: a case report and literature review.
2984059 - Involvement of the regulatory protein (ns) in the maturation of acth-sensitive adenylat...
12235109 - Differential effects of the early and late intrauterine environment on corticotrophic c...
576229 - Transient bitemporal hemianopsia during pregnancy after treatment of galactorrhea-ameno...
2216309 - Allometric growth of the adrenal gland in brazilian fetuses.
25177879 - Essential interventions for maternal, newborn and child health: background and methodol...
2239079 - Antithyroid drug treatment of graves' disease in pregnancy: long-term effects on somati...
17939249 - When is a cerclage indicated for cervical insufficiency? a literature review.
20171619 - Spontaneous ovarian hyperstimuation syndrome in a naturally conceived singleton pregnancy.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current medical research and opinion     Volume:  10     ISSN:  0300-7995     ISO Abbreviation:  Curr Med Res Opin     Publication Date:  1986  
Date Detail:
Created Date:  1986-09-17     Completed Date:  1986-09-17     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0351014     Medline TA:  Curr Med Res Opin     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  172-95     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Abnormalities, Drug-Induced / etiology
Adenoma / pathology,  surgery
Bromocriptine / adverse effects,  therapeutic use*
Endocrine Glands / drug effects
Hyperprolactinemia / blood,  drug therapy*
Infertility, Female / drug therapy*
Pituitary Neoplasms / pathology,  surgery
Pregnancy / drug effects
Pregnancy Complications / chemically induced
Pregnancy Complications, Neoplastic / pathology,  surgery
Prolactin / blood
Time Factors
Reg. No./Substance:
25614-03-3/Bromocriptine; 9002-62-4/Prolactin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Ultrasound monitored hepatic cryosurgery: longevity study on an animal model.
Next Document:  Distributions of vimentin and desmin filaments in embryonic cardiac muscle cells in culture.